GSK to acquire 35Pharma for $950 Million25 Feb 2026 07:20
There's further evidence again today that big bucks will be paid in our sector, with the news that GSK is to acquire 35Pharma for $950 Million. They are signing the deal for HS235, a potentially "best-in-class" inhibitor in clinical development for treatment of cardiopulmonary diseases. "Best in class" and "in clinical development" look and sound similar to where we are at currently. If GSK can pay nearly $1billion for a small player with an emerging pipeline of products then this obviously bodes well for Sareum with SRA 737, SDC1801 and SDC1802....
Good luck, Brighty